Comparative Pharmacology
Head-to-head clinical analysis: SULAR versus VERELAN PM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULAR versus VERELAN PM.
SULAR vs VERELAN PM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.
Verapamil is a calcium channel blocker that inhibits the influx of calcium ions across the cardiac and vascular smooth muscle cells, thereby reducing myocardial contractility, sinoatrial and atrioventricular node conduction, and vascular tone.
10-20 mg orally once daily; maximum 60 mg/day.
Verelan PM (verapamil hydrochloride) is an extended-release oral capsule administered once daily at bedtime. Typical adult dose for hypertension is 200 mg to 400 mg once daily at bedtime. Initial dose is 200 mg, titrated upward as needed. Maximum recommended dose is 400 mg daily.
None Documented
None Documented
Terminal half-life of 24-50 hours, mean ~34 hours; extended in elderly and hepatic impairment, dose adjustment may be needed
Terminal elimination half-life 7.2 ± 1.5 hours after oral administration, prolonged in hepatic impairment (up to 14-16 hours) and elderly; steady-state achieved after 3-4 days.
Renal: 50-60% as metabolites, 10% as unchanged drug; Fecal: ~35%; Biliary: <5%
Primarily hepatic metabolism (>95%), with 3-4% excreted unchanged in urine; biliary/fecal excretion accounts for <1% of unchanged drug.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker